JP2020532532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532532A5 JP2020532532A5 JP2020512430A JP2020512430A JP2020532532A5 JP 2020532532 A5 JP2020532532 A5 JP 2020532532A5 JP 2020512430 A JP2020512430 A JP 2020512430A JP 2020512430 A JP2020512430 A JP 2020512430A JP 2020532532 A5 JP2020532532 A5 JP 2020532532A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- aryl
- independently
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NZWHDUNFHQXOTO-MSBNIHEOSA-N CC1(C=C(C)C(C(Oc2ccc(CSP(OC[C@H]([C@H]3OP(O)(OC4)=O)O[C@@H](C[n]5c(ncnc6N)c6nc5)[C@@H]3F)(O[C@H]3[C@H](N(C=CC(N5)=O)C5=O)O[C@H]4[C@H]3F)=O)cc2)=O)=CC1)O Chemical compound CC1(C=C(C)C(C(Oc2ccc(CSP(OC[C@H]([C@H]3OP(O)(OC4)=O)O[C@@H](C[n]5c(ncnc6N)c6nc5)[C@@H]3F)(O[C@H]3[C@H](N(C=CC(N5)=O)C5=O)O[C@H]4[C@H]3F)=O)cc2)=O)=CC1)O NZWHDUNFHQXOTO-MSBNIHEOSA-N 0.000 description 1
- VWMJPWWSKOUJRY-SOELKDHPSA-N Cc(cc(cc1)O)c1C(Oc1ccc(CSP(OC[C@H]([C@H]([C@H]2F)OP(O)(OC3)=O)O[C@H]2[n]2c(ncnc4N)c4nc2)(O[C@H]2[C@H](N(C=CC(N4)=O)C4=O)O[C@H]3[C@H]2F)=O)cc1)=O Chemical compound Cc(cc(cc1)O)c1C(Oc1ccc(CSP(OC[C@H]([C@H]([C@H]2F)OP(O)(OC3)=O)O[C@H]2[n]2c(ncnc4N)c4nc2)(O[C@H]2[C@H](N(C=CC(N4)=O)C4=O)O[C@H]3[C@H]2F)=O)cc1)=O VWMJPWWSKOUJRY-SOELKDHPSA-N 0.000 description 1
- QTCMGJGOJLFOAG-IJSWPQNOSA-N Cc(cc(cc1)O)c1C(Oc1ccc(CS[P@](OC[C@H]([C@H]2OP(O)(OC[C@H]3O[C@H]4CN(C=CC(N5)=O)C5=O)=O)O[C@@H](C[n]5c(/N=C\N)c(C(N)=C)nc5)[C@@H]2F)(O[C@@H]4[C@@H]3F)=O)cc1)=O Chemical compound Cc(cc(cc1)O)c1C(Oc1ccc(CS[P@](OC[C@H]([C@H]2OP(O)(OC[C@H]3O[C@H]4CN(C=CC(N5)=O)C5=O)=O)O[C@@H](C[n]5c(/N=C\N)c(C(N)=C)nc5)[C@@H]2F)(O[C@@H]4[C@@H]3F)=O)cc1)=O QTCMGJGOJLFOAG-IJSWPQNOSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023070638A JP7673118B2 (ja) | 2017-08-31 | 2023-04-24 | 化合物、組成物、及び疾患の治療方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762552473P | 2017-08-31 | 2017-08-31 | |
| US62/552,473 | 2017-08-31 | ||
| US201862664493P | 2018-04-30 | 2018-04-30 | |
| US62/664,493 | 2018-04-30 | ||
| PCT/US2018/048705 WO2019046511A1 (en) | 2017-08-31 | 2018-08-30 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023070638A Division JP7673118B2 (ja) | 2017-08-31 | 2023-04-24 | 化合物、組成物、及び疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532532A JP2020532532A (ja) | 2020-11-12 |
| JP2020532532A5 true JP2020532532A5 (OSRAM) | 2021-10-07 |
| JP7270608B2 JP7270608B2 (ja) | 2023-05-10 |
Family
ID=65526007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512430A Active JP7270608B2 (ja) | 2017-08-31 | 2018-08-30 | 化合物、組成物、及び疾患の治療方法 |
| JP2023070638A Active JP7673118B2 (ja) | 2017-08-31 | 2023-04-24 | 化合物、組成物、及び疾患の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023070638A Active JP7673118B2 (ja) | 2017-08-31 | 2023-04-24 | 化合物、組成物、及び疾患の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11638716B2 (OSRAM) |
| EP (1) | EP3675859A4 (OSRAM) |
| JP (2) | JP7270608B2 (OSRAM) |
| CA (1) | CA3074232A1 (OSRAM) |
| TW (1) | TWI688390B (OSRAM) |
| WO (1) | WO2019046511A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX390014B (es) | 2016-03-18 | 2025-03-20 | Immune Sensor Llc | Compuestos de dinucleótidos cíclicos y métodos de uso. |
| WO2018156625A1 (en) | 2017-02-21 | 2018-08-30 | Board Of Regents,The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
| EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE |
| EP3728282B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| SG11202011434SA (en) | 2018-06-01 | 2020-12-30 | Eisai R&D Man Co Ltd | Methods for the treatment of bladder cancer |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| WO2020092127A1 (en) | 2018-10-29 | 2020-05-07 | Venenum Biodesign, LLC | Novel sting agonists |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| EP3966222A4 (en) * | 2019-05-09 | 2023-10-04 | Aligos Therapeutics, Inc. | MODIFIED CYCLIC DI-NUCLEOSIDE COMPOUNDS AS STING MODULATORS |
| CN114340680A (zh) | 2019-07-05 | 2022-04-12 | 坦博公司 | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| KR20230011324A (ko) | 2020-05-15 | 2023-01-20 | 이뮨센서 테라퓨틱스, 인코포레이티드 | 면역 체크포인트 억제제를 사용한 sting 작용제 병용 치료 |
| EP4192506A1 (en) | 2020-08-07 | 2023-06-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| AU2022315305A1 (en) | 2021-07-23 | 2024-02-01 | Immunesensor Therapeutics, Inc. | Sting agonist combination treatments with cytokines |
| GB202304385D0 (en) | 2023-03-24 | 2023-05-10 | Prostate Cancer Res | Combinatorial IL-15 therapy |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013185052A1 (en) | 2012-06-08 | 2013-12-12 | Aduro Biotech | Compostions and methods for cancer immunotherapy |
| BR112015013440B1 (pt) | 2012-12-13 | 2020-12-08 | Aduro Biotech, Inc | composições compreendendo dinucleotídeos de purina cíclicos com estereoquímicas |
| WO2014127378A2 (en) | 2013-02-18 | 2014-08-21 | Spring Bank Pharmaceuticals, Inc. | Design of short oligonucleotides as vaccine adjuvants and therapeutic agents |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| SI2996473T1 (sl) | 2013-05-18 | 2019-12-31 | Aduro Biotech, Inc. | Sestavki in postopki za aktiviranje signaliziranja, odvisnega od "stimulator interferonskih genov" |
| WO2015077354A1 (en) * | 2013-11-19 | 2015-05-28 | The University Of Chicago | Use of sting agonist as cancer treatment |
| CN114081946A (zh) | 2014-03-12 | 2022-02-25 | 耶达研究与开发有限公司 | 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤 |
| ES2692226T3 (es) | 2014-06-04 | 2018-11-30 | Glaxosmithkline Intellectual Property Development Limited | Dinucleótidos cíclicos como moduladores de STING |
| EP3035126B1 (fr) | 2014-12-18 | 2017-12-13 | The Swatch Group Research and Development Ltd. | Résonateur d'horlogerie à lames croisées |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
| CA2995365C (en) * | 2015-08-13 | 2021-10-12 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| AU2016343993A1 (en) | 2015-10-28 | 2018-05-10 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| CR20180286A (es) * | 2015-12-03 | 2018-07-16 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos de purina cíclicos como moduladores de sting |
| CN106540260A (zh) | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用 |
| WO2017106740A1 (en) * | 2015-12-16 | 2017-06-22 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production |
| US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| CN109451740B (zh) | 2016-01-11 | 2022-09-02 | 先天肿瘤免疫公司 | 用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸 |
| CA3016457A1 (en) | 2016-03-02 | 2017-09-08 | The Board Of Regents Of The University Of Texas System | Sting activating nanovaccine for immunotherapy |
| MX390014B (es) | 2016-03-18 | 2025-03-20 | Immune Sensor Llc | Compuestos de dinucleótidos cíclicos y métodos de uso. |
| EP3448393A1 (en) | 2016-04-25 | 2019-03-06 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| US20190345191A1 (en) | 2016-08-31 | 2019-11-14 | Innate Tumor Immunity, Inc. | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| CR20190168A (es) | 2016-10-04 | 2019-05-17 | Merck Sharp & Dohme | Compuestos de benzo[b]tiofeno como agonistas de sting |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| JP2020511420A (ja) | 2016-12-20 | 2020-04-16 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のためのｐｄ−１アンタゴニストと環状ジヌクレオチドｓｔｉｎｇアゴニストとの組み合わせ |
| JP2020503303A (ja) | 2016-12-20 | 2020-01-30 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のための環状ジヌクレオチドｓｔｉｎｇアゴニスト |
| WO2018156625A1 (en) | 2017-02-21 | 2018-08-30 | Board Of Regents,The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| WO2018208667A1 (en) | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| WO2018231752A1 (en) | 2017-06-12 | 2018-12-20 | University Of Miami | Sting-dependent activators for treatment of disease |
| JP2020524717A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの小分子調節因子 |
| TWI799426B (zh) | 2017-06-22 | 2023-04-21 | 英商克拉德夫製藥有限公司 | 人類ｓｔｉｎｇ之小分子調節劑 |
| JP2020524718A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの複素環式小分子調節因子 |
| WO2019027857A1 (en) | 2017-08-04 | 2019-02-07 | Merck Sharp & Dohme Corp. | COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER |
| MA49772A (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
| WO2019035901A1 (en) | 2017-08-15 | 2019-02-21 | University Of Miami | COMPOSITIONS AND METHODS FOR STING PROTEIN MODULATION |
| EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE |
| WO2019067468A1 (en) | 2017-09-26 | 2019-04-04 | La Jolla Institute For Allergy And Immunology | MODULATION OF THE IMMUNE RESPONSE THROUGH THE STING PROTEIN |
| AU2018368789B2 (en) | 2017-11-20 | 2022-06-02 | Stingthera, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
| US11633473B2 (en) | 2017-11-27 | 2023-04-25 | Children's Medical Center Corporation | Stimulator of Interferon Genes (STING) ligands and uses thereof |
| WO2019125974A1 (en) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| EP3743103A4 (en) | 2018-01-26 | 2021-03-17 | The Regents of The University of California | INTRANASAL ADMINISTRATION OF CYCLIC DI-NUCLEOTIDE ADJUVED VACCINE FOR TUBERCULOSIS |
| WO2019161171A1 (en) | 2018-02-16 | 2019-08-22 | Sperovie Biosciences, Inc. | Nanoparticle formulations of sting agonists |
| WO2019165032A1 (en) | 2018-02-21 | 2019-08-29 | The Scripps Research Institute | Agonists of stimulator of interferon genes sting |
| CA3097850A1 (en) | 2018-03-26 | 2019-10-03 | University Of Miami | Recombinant viral vector and uses thereof |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| CN111971277B (zh) | 2018-04-03 | 2023-06-06 | 默沙东有限责任公司 | 作为sting激动剂的苯并噻吩及相关化合物 |
| US20210228648A1 (en) | 2018-06-04 | 2021-07-29 | Aarhus Universitet | Worm products and methods of use |
| WO2019238786A1 (en) | 2018-06-12 | 2019-12-19 | Ryvu Therapeutics S.A. | Modulators of stimulator of interferon genes (sting) |
| CN108498529A (zh) | 2018-06-20 | 2018-09-07 | 福建师范大学 | 用于肿瘤预防治疗的DNA甲基转移酶抑制剂与cGAMP药物组合物 |
| WO2019243825A1 (en) | 2018-06-21 | 2019-12-26 | Curadev Pharma Limited | Small molecule modulators of human sting, conjugates and therapeutic applications |
| WO2019243823A1 (en) | 2018-06-21 | 2019-12-26 | Curadev Pharma Limited | Azaheterocyclic small molecule modulators of human sting |
| CN112823036B (zh) | 2018-07-03 | 2024-11-08 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| WO2020010451A1 (en) | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| AU2019311031A1 (en) | 2018-07-23 | 2021-03-18 | Fosun Orinove Pharmatech, Inc. | IRE1α inhibitor in combination with cancer therapeutic agent for cancer treatment |
-
2018
- 2018-08-30 EP EP18850903.8A patent/EP3675859A4/en active Pending
- 2018-08-30 WO PCT/US2018/048705 patent/WO2019046511A1/en not_active Ceased
- 2018-08-30 CA CA3074232A patent/CA3074232A1/en active Pending
- 2018-08-30 JP JP2020512430A patent/JP7270608B2/ja active Active
- 2018-08-30 US US16/643,393 patent/US11638716B2/en active Active
- 2018-08-31 TW TW107130548A patent/TWI688390B/zh active
-
2023
- 2023-04-24 JP JP2023070638A patent/JP7673118B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532532A5 (OSRAM) | ||
| JP2017526677A5 (OSRAM) | ||
| JP2019511483A5 (OSRAM) | ||
| JP2016529324A5 (OSRAM) | ||
| JP2019518766A5 (OSRAM) | ||
| JP2019527202A5 (OSRAM) | ||
| JP2020507589A5 (OSRAM) | ||
| JP2014521688A5 (OSRAM) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| JP2017531619A5 (OSRAM) | ||
| JP2005523922A5 (OSRAM) | ||
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| JP2019526596A5 (OSRAM) | ||
| JP2013056886A5 (OSRAM) | ||
| JP2012519691A5 (OSRAM) | ||
| RU2012110007A (ru) | Имидазохинолины в качестве двойных ингибиторов липидкиназы и mtor | |
| ES2702911T3 (es) | Agente antitumoral que incluye una baja dosis de clorhidrato de irinotecán hidratado | |
| JP2009513703A5 (OSRAM) | ||
| JP2014518882A5 (OSRAM) | ||
| JP2012516900A5 (OSRAM) | ||
| JP2016040288A5 (OSRAM) | ||
| JP2013521291A5 (OSRAM) | ||
| JP2017517565A5 (OSRAM) | ||
| JP2015536954A5 (OSRAM) | ||
| JP2019501879A5 (OSRAM) |